Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in PD-L1-positive HR-positive/HER2-negative metastatic breast cancer
NL-OMON51870Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON51870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51870.